EPI-001
EPI-001, a selective inhibitor of Androgen Receptor (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC50 of ~6 μM. EPI-001 is also a selective modulator of PPARγ. EPI-001 is active against castration-resistant prostate cancer[1][2][3].
Product Specifications
CAS Number
227947-06-0
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Androgen Receptor; Apoptosis; PPAR
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/epi-001.html
Purity
99.34
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
OCC(O)COC1=CC=C(C(C)(C2=CC=C(OCC(O)CCl)C=C2)C)C=C1
Molecular Formula
C21H27ClO5
Molecular Weight
394.89
Precautions
H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TAK1 (MAP3K7) pThr187 Rabbit Polyclonal Antibody
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF740 conjugate, 0.1mg/mL
